戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 (18:3n-6) was positively associated with all fibrocystic and cancerous conditions.
2 n normal and human breast cancer cell lines (fibrocystic and metastatic states) as well as normal and
3  more than 10% of patients and can result in fibrocystic architectural distortion of the lung, which
4  and the n-7 saturation index against benign fibrocystic breast changes and the progression of prolif
5 ation of n-3 fatty acids with risk of benign fibrocystic breast changes.
6                          Women who developed fibrocystic breast conditions classified as nonprolifera
7 eoporosis, breast cancer, endometriosis, and fibrocystic breast disease and has been hypothesized to
8 stic algorithm to distinguish normal tissue, fibrocystic change (FCC), fibroadenoma, and breast cance
9 0%) were benign, with common diagnoses being fibrocystic change (n = 20), stromal fibrosis (n = 10),
10 ules and ducts, at higher levels in areas of fibrocystic change and papillomas, in all benign breast
11 t LOH occurs frequently in the components of fibrocystic change as well as in normal TDLUs and sugges
12 2 cases containing the various components of fibrocystic change in the absence of malignancy were stu
13 vivo samples of human breast tissue (normal, fibrocystic change, fibroadenoma, and infiltrating carci
14 h atypia (EPA; HR, 1.81; 95% CI, 1.07-3.07), fibrocystic changes (HR, 1.60; 95% CI, 1.03-2.48), and c
15 angiomatous stromal hyperplasia (n = 6), and fibrocystic changes (n = 6).
16                                              Fibrocystic changes and benign fibroadenomas were identi
17 he breast and to evaluate the progression of fibrocystic changes in breast cancer.
18    Eight patients (4.4%) had benign results: fibrocystic changes in four, atypical ductal hyperplasia
19     These lesions display characteristics of fibrocystic changes observed in breasts of women, and in
20 hildhood that is clinically characterized by fibrocystic changes of the kidneys and the liver.
21 isease (ARPKD) is characterized by bilateral fibrocystic changes resulting in pronounced kidney enlar
22 RhoC was not expressed in any of the normal, fibrocystic changes, atypical hyperplasia, or ductal car
23 ystic conditions (PFCs) and nonproliferative fibrocystic conditions (NPFCs) in the breast and to eval
24 s in the development of benign proliferative fibrocystic conditions (PFCs) and nonproliferative fibro
25 are, the phenotype of BPD has evolved from a fibrocystic disease affecting late preterm infants to on
26 l papilloma as the source of discharge, with fibrocystic disease and ductal ectasia providing the nex
27 l carcinoma, and the third had proliferative fibrocystic disease of the breast.
28 lls) of benign tumors from ten patients with fibrocystic disease of the breast.
29 ve polycystic kidney disease is a hereditary fibrocystic disease that involves the kidneys and the bi
30          There were no differences in breast fibrocystic disease, uterine fibroids, or endometrial li
31  benign conditions, such as fibroadenoma and fibrocystic disease.
32 pithelial cells obtained from a patient with fibrocystic disease.
33 dney disease (ARPKD) is a severe hepatorenal fibrocystic disorder.
34  differential diagnosis in young adults with fibrocystic hepatorenal disease.
35 ith progressive degenerative liver fibrosis, fibrocystic kidney disease, and hypertrophic cardiomyopa
36 e, as well as progressive retinal dystrophy, fibrocystic kidney disease, and liver fibrosis.
37 ted high-grade breast tumors into low-grade, fibrocystic-like structures.
38                                     Although fibrocystic liver disease is an established ciliopathy p
39 vealing 15 fibroadenomas, 12 carcinomas, six fibrocystic nodules, and 13 other lesions.
40  congenital kidney developmental defects and fibrocystic pathologies.
41 ve treatments are not available for advanced fibrocystic pulmonary disease.
42 not with normal breast, benign papilloma, or fibrocystic tissue.
43 ence of events linking the genetic defect to fibrocystic trait of cholangiocytes in CHF.
44 n of cancer as compared with both normal and fibrocystic tumor tissue was measured in all the samples